Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01GlobeNewsWire · 1 day ago
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01GlobeNewsWire · 5 days ago
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual MeetingGlobeNewsWire · Oct 2, 2026
Analyzing Nektar Therapeutics (NASDAQ:NKTR) & Evaxion A/S (NASDAQ:EVAX)Defense World · Sep 17, 2026
Evaxion applies its AI-Immunology™ platform in autoimmune diseasesGlobeNewsWire · Sep 14, 2026
Evaxion A/S (EVAX) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 20, 2026Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.01 | -$0.01 | Beat |
| May 26, 2026 | -$0.01 | -$0.01 | Beat |
| Mar 5, 2026 | -$0.25 | -$0.02 | Beat |
| Oct 30, 2025 | -$0.01 | $0.01 | Beat |
| Aug 14, 2025 | -$0.50 | -$0.76 | Miss |
| May 27, 2025 | -$0.65 | -$0.29 | Beat |